Nathan Mata is a clinical research professional with more than 15+ years of experience working with R&D and clinical development teams to advance investigational therapeutics through clinical study. Nathan possesses a wide breadth of scientific and clinical research knowledge with extensive practice in scientific due diligence and gap analysis, formulation of drug development strategies, and clinical study designs. Nathan’s clinical development and operations experience includes cross-functional collaboration in the management of Phase I-III studies, including NDA submissions and approvals.
Prior to joining Halloran, Nathan held various leadership positions in R&D and clinical development. Most recently, Nathan has worked as a Clinical Research and Operations Consultant assisting biotech companies in the execution of IND-enabling studies and Phase I–III trial designs for indications in ophthalmology and oncology. Prior to that, Nathan was the Chief Operating Officer at Trethera Corporation, a start-up oncology company focused on the treatment of blood cancers. While at Trethera, Nathan oversaw daily company operations and played a key role in the advancement of small molecule therapeutics from academic research, through IND enabling and into clinical study. Nathan has also played a key role in the founding and management of start-up biotech companies in San Diego, CA (Sytera, Inc. Sirion Therapeutics, and Revision Therapeutics). For each of these companies, Nathan designed and executed R&D roadmaps, managed R&D and clinical study teams, and functioned as an executive leader on various clinical project teams.
Nathan received his education at The University of Texas where he earned a doctorate in Neurobiology, a Master of Science in Biochemistry, and a Bachelor of Science in Biology. Nathan has also held a Research Faculty position at Jules Stein Eye Institute on the campus of The University of California at Los Angeles.